Drug Ther Bull. 2011 Oct;49(10):114-7. doi: 10.1136/dtb.2011.02.0060.
Dabigatran etexilate (Pradaxa - Boehringer Ingelheim) is an oral anticoagulant that has been licensed in the EU since 2008 for thromboprophylaxis in adults following a hip or knee joint replacement. The marketing authorisation for the drug in the EU has recently been extended to include the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). In theory, dabigatran could offer an advantage to patients who need anticoagulation because, unlike warfarin, its dose does not need to be individually adjusted and its effects do not require regular monitoring through blood sampling. Here we review the evidence for dabigatran in this new indication and consider its place in the management of patients with AF.
达比加群酯（Pradaxa - 勃林格殷格翰公司）是一种口服抗凝剂，自2008年起在欧盟获得许可，用于成人髋关节或膝关节置换术后的血栓预防。该药物在欧盟的上市许可最近已扩大到包括预防非瓣膜性心房颤动（AF）患者的中风和全身性栓塞。理论上，达比加群可能为需要抗凝治疗的患者带来优势，因为与华法林不同，其剂量无需个体化调整，且其效果无需通过采血进行定期监测。在此，我们回顾达比加群在这一新适应症方面的证据，并探讨其在房颤患者管理中的地位。
